Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:
a. Adalimumab – Humira
b. Adalimumab Biosimilar
c. Filgotinib
d. Golimumab
e. Infliximab – Remicade
f. Infliximab Biosimilar
g. Ozanimod
h. Tofacitinib
i. Ustekinumab
j. Vedolizumab
Q2 If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:
a. Adalimumab – Humira
b. Adalimumab Biosimilar
c. Filgotinib
d. Golimumab
e. Infliximab – Remicade
f. Infliximab Biosimilar
g. Ozanimod
h. Tofacitinib
i. Ustekinumab
j. Vedolizumab
